CUDC-101

DB12174

small molecule investigational

Deskripsi

CUDC-101 has been used in trials studying the treatment of Cancer, Tumors, Liver Cancer, Breast Cancer, and Gastric Cancer, among others.

Struktur Molekul 2D

Berat 434.496
Wujud -

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

404 Data
Ivabradine Ivabradine may increase the QTc-prolonging activities of CUDC-101.
Vorinostat The risk or severity of gastrointestinal bleeding and thrombocytopenia can be increased when CUDC-101 is combined with Vorinostat.
Dofetilide The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Dofetilide.
Citalopram The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Citalopram.
Anagrelide The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Anagrelide.
Disopyramide The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Disopyramide.
Clemastine The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Clemastine.
Ibutilide The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Ibutilide.
Valproic acid The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Valproic acid.
Terfenadine The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Terfenadine.
Grepafloxacin The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Grepafloxacin.
Quinine The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Quinine.
Sotalol The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Sotalol.
Erlotinib The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Erlotinib.
Toremifene The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Toremifene.
Cisapride The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Cisapride.
Imatinib The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Imatinib.
Astemizole The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Astemizole.
Thioridazine The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Thioridazine.
Trovafloxacin The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Trovafloxacin.
Mifepristone The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Mifepristone.
Cocaine The risk or severity of methemoglobinemia can be increased when CUDC-101 is combined with Cocaine.
Quinidine The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Quinidine.
Procainamide The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Procainamide.
Pimozide The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Pimozide.
Amiodarone The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Amiodarone.
Arsenic trioxide The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Arsenic trioxide.
Escitalopram The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Escitalopram.
Domperidone The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Domperidone.
Sparfloxacin The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Sparfloxacin.
Halofantrine The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Halofantrine.
Bepridil The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Bepridil.
Paliperidone The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Paliperidone.
Lithium cation The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Lithium cation.
Temafloxacin The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Temafloxacin.
Zuclopenthixol The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Zuclopenthixol.
Tetrabenazine The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Tetrabenazine.
Dronedarone The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Dronedarone.
Nilotinib The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Nilotinib.
Iloperidone The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Iloperidone.
Vandetanib The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Vandetanib.
Romidepsin The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Romidepsin.
Asenapine The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Asenapine.
Artemether The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Artemether.
Lumefantrine The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Lumefantrine.
Vemurafenib The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Vemurafenib.
Eliglustat The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Eliglustat.
Ribociclib The risk or severity of QTc prolongation can be increased when Ribociclib is combined with CUDC-101.
Glasdegib The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Glasdegib.
Deutetrabenazine The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Deutetrabenazine.
Macimorelin The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Macimorelin.
Terodiline The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Terodiline.
Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with CUDC-101.
Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with CUDC-101.
Erythromycin The risk or severity of QTc prolongation can be increased when Erythromycin is combined with CUDC-101.
Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with CUDC-101.
Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with CUDC-101.
Ranolazine The risk or severity of QTc prolongation can be increased when Ranolazine is combined with CUDC-101.
Sulfisoxazole The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with CUDC-101.
Amitriptyline The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with CUDC-101.
Methadone The risk or severity of QTc prolongation can be increased when Methadone is combined with CUDC-101.
Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with CUDC-101.
Clozapine The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Clozapine.
Sulpiride The risk or severity of QTc prolongation can be increased when Sulpiride is combined with CUDC-101.
Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with CUDC-101.
Promazine The risk or severity of QTc prolongation can be increased when Promazine is combined with CUDC-101.
Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with CUDC-101.
Droperidol The risk or severity of QTc prolongation can be increased when Droperidol is combined with CUDC-101.
Imipramine The risk or severity of QTc prolongation can be increased when Imipramine is combined with CUDC-101.
Chlorpromazine The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with CUDC-101.
Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with CUDC-101.
Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with CUDC-101.
Fluorouracil The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with CUDC-101.
Perflutren The risk or severity of QTc prolongation can be increased when Perflutren is combined with CUDC-101.
Cinnarizine The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with CUDC-101.
Atropine The risk or severity of QTc prolongation can be increased when Atropine is combined with CUDC-101.
Chloroquine The risk or severity of QTc prolongation can be increased when Chloroquine is combined with CUDC-101.
Efavirenz The risk or severity of QTc prolongation can be increased when Efavirenz is combined with CUDC-101.
Adenosine The risk or severity of QTc prolongation can be increased when Adenosine is combined with CUDC-101.
Pentamidine The risk or severity of QTc prolongation can be increased when Pentamidine is combined with CUDC-101.
Gadobenic acid The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with CUDC-101.
Carbinoxamine The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with CUDC-101.
Dolasetron The risk or severity of QTc prolongation can be increased when Dolasetron is combined with CUDC-101.
Roxithromycin The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with CUDC-101.
Nalidixic acid The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with CUDC-101.
Cinoxacin The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with CUDC-101.
Loperamide The risk or severity of QTc prolongation can be increased when Loperamide is combined with CUDC-101.
Granisetron The risk or severity of QTc prolongation can be increased when Granisetron is combined with CUDC-101.
Ondansetron The risk or severity of QTc prolongation can be increased when Ondansetron is combined with CUDC-101.
Levosimendan The risk or severity of QTc prolongation can be increased when Levosimendan is combined with CUDC-101.
Mesoridazine The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with CUDC-101.
Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with CUDC-101.
Telithromycin The risk or severity of QTc prolongation can be increased when Telithromycin is combined with CUDC-101.
Lomefloxacin The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with CUDC-101.
Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with CUDC-101.
Primaquine The risk or severity of QTc prolongation can be increased when Primaquine is combined with CUDC-101.
Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with CUDC-101.
Chlorpheniramine The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with CUDC-101.
Nifedipine The risk or severity of QTc prolongation can be increased when Nifedipine is combined with CUDC-101.
Levofloxacin The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with CUDC-101.

Target Protein

Epidermal growth factor receptor EGFR
Receptor tyrosine-protein kinase erbB-2 ERBB2

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul